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Fenamate NSAIDs inhibit the NLRP3
inﬂammasome and protect against Alzheimer’s
disease in rodent models
Michael J.D. Daniels1,*, Jack Rivers-Auty1,*, Tom Schilling2, Nicholas G. Spencer2, William Watremez3,
Victoria Fasolino3, Sophie J. Booth1, Claire S. White1, Alex G. Baldwin3, Sally Freeman3, Raymond Wong1,
Clare Latta1, Shi Yu1, Joshua Jackson3, Nicolas Fischer4, Violette Koziel4, Thierry Pillot4, James Bagnall1,
Stuart M. Allan1, Pawel Paszek1, James Galea5, Michael K. Harte3, Claudia Eder2, Catherine B. Lawrence1
& David Brough1
Non-steroidal anti-inﬂammatory drugs (NSAIDs) inhibit cyclooxygenase-1 (COX-1) and
COX-2 enzymes. The NLRP3 inﬂammasome is a multi-protein complex responsible for the
processing of the proinﬂammatory cytokine interleukin-1b and is implicated in many
inﬂammatory diseases. Here we show that several clinically approved and widely used
NSAIDs of the fenamate class are effective and selective inhibitors of the NLRP3
inﬂammasome via inhibition of the volume-regulated anion channel in macrophages,
independently of COX enzymes. Flufenamic acid and mefenamic acid are efﬁcacious in
NLRP3-dependent rodent models of inﬂammation in air pouch and peritoneum. We also show
therapeutic effects of fenamates using a model of amyloid beta induced memory loss and a
transgenic mouse model of Alzheimer’s disease. These data suggest that fenamate NSAIDs
could be repurposed as NLRP3 inﬂammasome inhibitors and Alzheimer’s disease ther-
apeutics.
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S
ince their characterization as COX inhibitors1,
non-steroidal anti-inﬂammatory drugs (NSAIDs) have
been used to treat a wide variety of diseases with
relatively limited side effects2. NSAID inhibition of COX
prevents the conversion of arachidonic acid to eicosanoids
resulting in a reduction in the synthesis of proinﬂammatory
prostaglandins3. Evidence indicates a polyvalent effect of NSAIDs
with some research suggesting COX-independent activity4.
One such important action may be to directly limit the
production of proinﬂammatory cytokines.
Many inﬂammatory diseases are driven by the proinﬂammatory
cytokine interleukin-1b (IL-1b)5. IL-1b is produced in myeloid
cells as an inactive precursor (pro-IL-1b) that requires cleavage by
the protease caspase-1 for its activation and secretion6.
Caspase-1 is also produced as an inactive precursor, which is
activated following recruitment to a large multi-protein complex
called the inﬂammasome6. Inﬂammasomes are deﬁned by the
presence of a pattern recognition receptor. The best characterized
inﬂammasome-forming pattern recognition receptor, and the
most commonly associated with disease is NLRP3 (NLR
family, pyrin domain containing 3). In response to pathogen-
associated molecular patterns or damage-associated molecular
patterns NLRP3 nucleates the oligomerization of ASC
(apoptosis-associated speck-like protein containing a caspase
recruitment domain) molecules7,8 into large ‘specks’ that serve as
platforms for caspase-1 activation and subsequent release of IL-1b.
The NLRP3 inﬂammasome is an important contributor to
inﬂammatory diseases, including Alzheimer’s disease9,
atherosclerosis10, metabolic diseases such as type 2 diabetes11
and others12. Hence, there is substantial interest in the
discovery of potentially therapeutic inﬂammasome inhibitors.
One such compound, MCC950, has been identiﬁed as a
potent NLRP3-selective inhibitor13, but is not yet available for
clinical use. Fenamate NSAIDs have been shown to inhibit IL-1b
secretion from macrophages14, although the signiﬁcance of COX
inhibition remains unclear15. Here we show that the fenamate
class of NSAIDs inhibit the NLRP3 inﬂammasome via reversible
blockade of volume-regulated anion channels (VRAC) in the
plasma membrane, and inhibit cognitive impairments in
models of Alzheimer’s disease in rodents, thus offering a safe
and rapidly translatable option to treat NLRP3-related
inﬂammatory diseases.
Results
Fenamate NSAIDs selectively inhibit the NLRP3 inﬂammasome.
Immortalized mouse bone marrow-derived macrophages
(iBMDMs) were primed with lipopolysaccharide (LPS; 1mgml 1,
2 h), after which the media was replaced with serum-free media.
At this point the cells were incubated with a range of
NSAIDs (Supplementary Fig. 1) for 15min before 1 h stimulation
with 5mM ATP to activate the P2X7 receptor and induce
NLRP3 inﬂammasome activation16. ELISA analysis of cell
supernatants revealed that of the NSAIDs tested the fenamates
(N-phenyl-substituted anthranilic acid derivatives such as
ﬂufenamic acid, meclofenamic acid, mefenamic acid) were most
effective at inhibiting IL-1b release (Fig. 1a). The selective COX-2
inhibitor celecoxib did not inhibit IL-1b release, nor did ibuprofen,
even at concentrations supra-maximal for COX inhibition.
Western blot analysis of the supernatants also showed that
caspase-1-dependent processing of IL-1b was also inhibited by
the fenamates (Supplementary Fig. 2). Fenamate NSAIDs had no
effect on ATP-induced cell death (Supplementary Fig. 3)
suggesting that their effects were speciﬁc to IL-1b release, and
independent of the stability of ATP. As early studies indicated
multiple sites of action for the fenamate NSAIDs17, these data
reveal the fenamates as inhibitors of IL-1b processing and release
and suggest that this effect is independent of COX inhibition.
Flufenamic acid, but not ibuprofen, also inhibited IL-1b release
induced by the NLRP3 inﬂammasome activator monosodium
urate (MSU) in primary mouse BMDMs (Fig. 1b), suggesting that
their effect was not due to direct inhibition of the P2X7 receptor
or a direct effect on ATP. To determine whether the fenamates
were selective inhibitors of NLRP3-dependent IL-1b release,
we tested their effects against other well-characterized
inﬂammasomes in primary BMDMs. NLRC4 inﬂammasome
activation by transfected Salmonella typhimurium ﬂagellin in
BMDMs induced IL-1b release, which was not inhibited by
ﬂufenamic or mefenamic acid (Fig. 1c). AIM2 inﬂammasome
activation by transfected double-stranded DNA was also
unaffected by ﬂufenamic or mefenamic acid (Fig. 1d).
These data suggest that the fenamates selectively inhibit the
NLRP3 pathway.
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Figure 1 | Fenamate NSAIDs inhibit IL-1b processing and release.
(a) iBMDMs were primed with LPS (1 mgml 1, 2 h) then pre-treated with
NSAID at indicated concentration before stimulating with ATP (5mM, 1 h).
(b–d) Murine primary BMDMs from WT (b) or NLRP3 / (c,d) mice
were primed with LPS (1 mgml 1, 4 h) and pre-treated with NSAID
(100mM, 15min) before stimulating with monosodium urate (MSU)
crystals (250mgml 1, 4 h) (b), transfected ultrapure ﬂagellin from
Salmonella typhimurium (1 ng per 1,000 cells, 2 h) (c), or transfected
DNA (0.66 ng per 1,000 cells, 4 h) (d). Supernatants were analysed by
ELISA. Data are presented as mean % IL-1b release versus vehicle
(DMSO) controlþ s.e.m (n¼ 3 or 4). NS, not signiﬁcantly different,
*Po0.05, **Po0.01 determined by one-sample t-test versus hypothetical
value of 100%.
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iBMDMs were transduced with lentivirus to stably express the
inﬂammasome adaptor ASC fused to mCherry. Inﬂammasome
activation in these cells results in the aggregation of ASC into
one large ASC speck in the cytoplasm that is readily visible by
ﬂuorescence microscopy. ASC–mCherry expressing iBMDMs
were treated with LPS (1 mgml 1, 2 h) and then ATP (5mM)
in serum-free media plus or minus a 15min pre-incubation
with ibuprofen, mefenamic acid or ﬂufenamic acid (all 100 mM).
Flufenamic and mefenamic acid both inhibited NLRP3-
dependent ASC speck formation whereas ibuprofen had no
effect (Fig. 2a). In addition to inhibiting IL-1b release from
mouse cells, ﬂufenamic acid also inhibited IL-1b release (Fig. 2b)
and production of the active p10 subunit of caspase-1 (Fig. 2c)
from nigericin-treated human THP-1 cells. These data show
that the fenamates inhibited NLRP3-dependent IL-1b release
upstream of ASC speck formation.
Chloride channels regulate the effects of fenamates on NLRP3.
To further identify the mechanism of action of fenamates on
NLRP3, we sought to determine the reversibility of fenamate
inhibition of NLRP3-dependent IL-1b release. Flufenamic acid did
not react with protected cysteine in contrast to 3,4-methylene-
dioxy-b-nitrostyrene (MNS; Supplementary Fig. 4), a known
inhibitor of NLRP3 via irreversible cysteine modiﬁcation18,19. Thus
the mechanism of fenamate action does not involve irreversible
cysteine modiﬁcation. Following the secretion protocol above,
except with three media changes over 15min to wash out the
fenamates ﬂufenamic acid and mefenamic acid, the reversible
caspase-1 inhibitor Ac-YVAD-cho, and the irreversible NLRP3
inhibitor MNS, it was revealed that the inhibitory effects of the
fenamates on NLRP3-dependent IL-1b release were fully
reversible (Fig. 3a). A further experiment, with just one wash,
which failed to remove the inhibitor effects of YVAD, completely
reversed the effects of ﬂufenamic and mefenamic acid on NLRP3
inﬂammasome inhibition (Fig. 3b) strongly suggesting that their
inhibitory effects were at the plasma membrane. Flufenamic
acid is a well-established modulator of ion channels20. Thus
we ﬁrst-tested the effects of the ﬂufenamic and mefenamic
acid on ATP-induced cation currents in LPS-primed iBMDMs
using whole-cell patch clamp recordings. Neither ﬂufenamic nor
mefenamic acid inhibited ATP-induced cation currents (Fig. 3c–e),
nor inhibited ATP-induced increases in intracellular Ca2þ or
Naþ levels (Supplementary Fig. 5). Flufenamic acid is also known
to inhibit Cl currents20 and so we tested the effects of the
fenamates on VRAC. VRAC currents measured by whole-cell
patch clamp in LPS (1mgml 1, 4 h) primed iBMDMs were
induced by hypotonicity, also a known activator of the NLRP3
inﬂammasome21. Both ﬂufenamic and mefenamic acid inhibited
VRAC, while non-NLRP3 inhibiting NSAIDs such as ibuprofen
and diclofenac had no effect (Fig. 3f–j). In light of these data we
tested whether other Cl channel inhibitors would block
NLRP3-dependent IL-1b release. In LPS-primed iBMDMs, a
15min pre-incubation with either of the Cl channel inhibitors
NPPB (100mM) or 4,40-diisothiocyanatostilbene-2,20-disulfonic
acid disodium salt hydrate (DIDS; 100mM) completely
prevented NLRP3-inﬂammasome-dependent IL-1b release
(Fig. 3k). To further conﬁrm the importance of Cl currents,
and in particular the importance of VRAC, we used the speciﬁc
VRAC inhibitor DCPIB (10mM), which also completely inhibited
ATP-induced IL-1b release (Fig. 3l). Flufenamic acid and DCPIB
also inhibited the regulatory volume decrease induced by
hypotonicity in THP-1 cells, which is known to require
Cl efﬂux22 (Supplementary Fig. 6). These data suggest that the
mechanism of action of the fenamate NSAIDs on the NLRP3
inﬂammasome is via an inhibition of the Cl channel VRAC.
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Figure 2 | Fenamate NSAIDs inhibit ASC speck formation and caspase-1
activation. (a) iBMDMs stably expressing ASC protein conjugated to
mCherry were primed with LPS (1mgml 1, 2 h) then pre-treated with
selected drug (100mM, 15min) before stimulation with ATP (5mM,
30min) under live microscopy. Formation of ASC specks (examples
indicated by white arrows) was quantiﬁed (lower right) and presented as
mean % specks counted versus vehicleþ s.e.m (n¼4). Scale bars are
20mm. (b,c) THP-1 cells were primed with LPS (1mgml 1, 4 h) and
pre-treated with NSAID (200mM, 15min) before stimulating with nigericin
(10 mM, 1 h). Supernatants were taken and analysed for IL-1b by ELISA
(b) and the p10 active subunit of caspase-1 by western blot (c). ELISA data
are presented as mean % IL-1b release versus vehicle (DMSO)
controlþ s.e.m (n¼ 3). *Po0.05, ***Po0.001 determined by one-sample
t-test versus hypothetical value of 100%.
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Fenamates inhibit NLRP3 inﬂammasomes in vivo. We next
tested whether the fenamates would have any effect on the
NLRP3 inﬂammasome in vivo. Initially, we used a mouse air
pouch model in which MSU-induced IL-1b production is NLRP3
inﬂammasome dependent23. Seven days after the air pouches
were raised in the dorsum of C57BL/6 mice they were injected
with MSU crystals (3mg in 1ml sterile saline) or vehicle with or
without ﬂufenamic acid (20mg kg 1 in sterile saline, 5%
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Figure 3 | Fenamates inhibit NLRP3 via reversible blockade of the Cl channel VRAC. (a) iBMDMs were primed with LPS (1 mgml 1, 4 h) and pre-
treated with NSAID, reversible caspase-1 inhibitor YVAD-CHO or irreversible NLRP3 inhibitor 3,4-methylenedioxy-b-nitrostyrene (MNS) (100mM, 15min)
before washing 3 5min (or no wash) and stimulation with ATP (5mM, 1 h). (b) Cells were pre-treated with drug as above before either media
replacement without drug, media replacement with drug or no media replacement followed by ATP stimulation. (c–e) iBMDMs were primed as above.
Currents were measured in the whole-cell conﬁguration of the patch clamp technique. Voltage ramps were applied from  90mV to þ 90mV for a
duration of 360ms every 20 s. Non selective cation currents were evoked by 5mM ATP and were measured in the absence (ATP) or presence of 100 mM
ﬂufenamic acid (c, n¼ 8) or mefenamic acid (d, n¼ 10). (f–j) iBMDMs were primed as above before whole-cell volume-regulated chloride currents (VRAC)
were induced by hypotonic extracellular medium. Currents were induced by 360ms-lasting voltage ramps from  90mV to þ 90mVevery 20 s. Examples
of current recordings measured in the absence or presence of 100mM ibuprofen (f, n¼6), diclofenac (g, n¼ 5), ﬂufenamic acid (h, n¼6), or mefenamic
acid (i, n¼6). ***Po0.001, NS, not signiﬁcantly different, determined by one-sample t-test versus hypothetical value of 100%. (K) iBMDMs were primed
as above and pre-treated with ﬂufenamic acid, mefenamic acid, Cl channel blockers NPPB or DIDS (100mM, 15min) before stimulation with ATP (5mM,
1 h). (l) iBMDMs were primed as above and pre-treated with DCPIB (10mM, 15min) before stimulation with ATP (5mM, 1 h). IL-1b in the supernatants
(a,b,k,l) was quantiﬁed by ELISA and data are presented as mean % IL-1b release versus vehicle (DMSO) controlþ s.e.m or mean IL-1b release (n¼4).
*Po0.05, **Po0.01, ***Po0.001, NS, not signiﬁcantly different determined by one-way ANOVA with Tukey’s post hoc analysis (a) or one-sample t-test
versus hypothetical value of 100% (b–k). ###Po0.001 versus ATP (l).
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Cremaphor EL, 5% dimethyl sulfoxide (DMSO)) or vehicle. Six
hours later pouches were lavaged and IL-1b measured by
ELISA. Flufenamic acid signiﬁcantly inhibited MSU-induced
IL-1b production in the pouch (Supplementary Fig. 7). Flow
cytometry was performed on lavage samples collected from
the air pouch and a speciﬁc MSU-dependent recruitment of
macrophages/monocytes was observed (Supplementary Fig. 7).
Flufenamic acid also inhibited MSU-induced macrophage/
monocyte recruitment (Supplementary Fig. 7). We also tested
mefenamic acid in a NLRP3-dependent peritoneal model of
inﬂammation. LPS injection into the peritoneum induces low
levels of IL-1b that are greatly enhanced with the co-addition of
the NLRP3 agonist ATP24–26. In this model the IL-1b production
is completely dependent on P2X7 (ref. 25), an established
activator of the canonical NLRP3 inﬂammasome16, and is
inhibited by cytokine release inhibiting drugs developed
by Pﬁzer26, which are close analogues and precursors of the
NLRP3-selective inﬂammasome inhibitor MCC950 (ref. 13).
Wild-type and NLRP3 / mice were treated with LPS (1 mg in
0.5ml, intraperitoneal (i.p.)) for 4 h followed by ATP (100mM in
0.5ml) for 15min. Groups of wild-type mice were also dosed with
mefenamic acid, or MCC950 (both at 50mg kg 1, i.p.).
Peritoneums were lavaged, blood taken and lavage ﬂuid and
plasma were analysed by ELISA for IL-1b and IL-1a
(Supplementary Fig. 8). Peritoneal administration of LPS and
ATP induced signiﬁcant release of IL-1b that was completely
blocked by mefenamic acid and by MCC950 (Supplementary
Fig. 8). Furthermore, LPS and ATP did not cause IL-1b
release from NLRP3 / mice (Supplementary Fig. 8). These
data suggest that fenamates are effective inhibitors of the NLRP3
inﬂammasome in vivo.
We also tested the effect of fenamates in more disease relevant
models. Inﬂammation contributes to the progression of
Alzheimer’s disease27, and on-going research is establishing
the NLRP3-inﬂammasome as central to the development of
inﬂammation, pathology and memory deﬁcits in a mouse model
of Alzheimer’s disease9,28. Amyloid beta (Ab) is a causative factor
in the development of Alzheimer’s disease and is a known
activator of the NLRP3 inﬂammasome28. Mefenamic acid is used
routinely in clinical practice and so we tested the effects of
mefenamic acid in an in vivo model of Ab-induced memory
loss29. Rats injected intracerebroventricularly with soluble Ab1–42
oligomers or vehicle were also treated with daily injections of
mefenamic acid (5mg kg 1, i.p.) or vehicle for 14 days.
Mefenamic acid treatment prevented Ab1–42 induced memory
deﬁcits as measured using the novel object recognition (NOR)
test at day 14 (Fig. 4a, Supplementary Fig. 9). This protective
effect was sustained up to day 35, 21 days after the mefenamic
acid treatment had been terminated (Fig. 4b).
Following the acute Ab1–42 injection model, we then tested the
efﬁcacy of mefenamic acid in 3TgAD transgenic mice (a mouse
model for Alzheimer’s disease). For this we used a therapeutic
administration strategy beginning at an age where pathology and
memory deﬁcits have previously been described in the 3TgAD
model30. At 13–14 months of age administration of mefenamic
acid by osmotic minipump over 28 days (at 25mg kg 1 per day)
completely abated memory deﬁcits in the 3TgAD mice as
measured by NOR (Fig. 4c). The brains of these mice
were sectioned and stained for IL-1b and, using Iba1, for
microglia. Microglial activation states were scored by morphology
as described in the Methods section (Supplementary Fig. 10,
modiﬁed scale from published literature31,32). In 3TgAD mice
it has previously been established that amyloid pathology begins
to develop in the subiculum at around 12 months of age30.
We found that there was substantial microglial activation in the
subicula of 3TgAD mice, and that the activated/amoeboid
microglia expressed IL-1b (Fig. 4d–f, Supplementary Fig. 10).
No microglial activation or IL-1b expression was seen in other
regions of the brain (Supplementary Fig. 11). Mefenamic acid
treatment completely abated Alzheimer’s disease-related
neuroinﬂammation with levels of microglial activation and
IL-1b expression reduced to that of wild-type mice (Fig. 4d–f,
Supplementary Fig. 10).
Discussion
The NLRP3 inﬂammasome is an important contributor to
diverse inﬂammatory diseases including Alzheimer’s disease9,
atherosclerosis10, metabolic diseases such as type II diabetes11,
and others12. However, despite this, there are currently no
clinically available inhibitors of NLRP3. Here we show that
fenamate NSAIDs are selective inhibitors of the NLRP3
inﬂammasome. We also show that the fenamates inhibited the
membrane Cl channel VRAC. Given additional recent research
showing the importance of Cl channels in inﬂammasome
activation in response to hypotonicity21, we propose that the
effects of fenamates on NLRP3 are via inhibition of VRAC.
Furthermore we show that inhibiting this pathway was protective
and therapeutic in two animal models of Alzheimer’s disease.
Treatment with mefenamic acid of an established disease model
abated brain inﬂammation and memory deﬁcits suggesting that
inﬂammation is a druggable target for Alzheimer’s disease.
There has been a signiﬁcant decline in the number of new
therapies being translated to clinic in the last two decades33.
However, we now appreciate that the robustness of biological
systems depends on the network and there is an appreciation that
targeting multiple points in a pathway may be more efﬁcacious
than targeting a single node33,34. The fenamates inhibit COX
enzymes35, and as we report here, also inhibit the NLRP3
inﬂammasome. Therefore the fenamate NSAIDs are attractive
candidates for a polyvalent approach to treat inﬂammatory
disease. The mechanism of action of the fenamates in vivo may be
as much dependent on VRAC/NLRP3 as it is COX. We have
previously reported synergy between inhibitors in inﬂammatory
pathways to cause levels of inhibition far greater than observed
singly34. Thus the ability of molecules such as the fenamates to
modulate several points in a pathway is likely to confer greater
protective effects than molecules that have single targets, thus
allowing them to be effective at lower doses.
The selectivity of the fenamates to NLRP3 over other
inﬂammasomes reported here is another advantage since their
use would avoid compromising NLRC4 or AIM2 inﬂammasome-
dependent host responses to infection. The current strategies used
to target IL-1b in disease rely on biologicals such as the IL-1
receptor antagonist anakinra, or the neutralizing antibody
canakinumab36. While these are effective in some inﬂammatory
diseases, they are expensive and may not readily penetrate
tissues such as the brain. Thus, used as a monotherapy, or as an
adjunct to current therapies, there is real scope to consider
fenamate NSAIDs as a frontline treatment for inﬂammatory
disease.
Although there is robust evidence linking NLRP3 to
inﬂammatory disease from animal models (cited above), apart
from the cryopyrin-associated periodic syndromes, there is
limited evidence in humans. Further characterization of human
inﬂammatory disorders may widen the scope for use of fenamate
NSAIDs to target NLRP3 in human disease. Given that some
fenamate NSAIDs are already routinely used clinically, and their
pharmacokinetic and toxicity proﬁles are well established37
encouraging results in animal studies could lead rapidly to
clinical efﬁcacy trials in inﬂammatory diseases. Additional
epidemiological studies to assess beneﬁts to patients taking
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Figure 4 | Mefenamic acid is protective in rodent models of Alzheimer’s disease through an anti-inﬂammatory mechanism. (a,b) Female Lister hooded
rats (200–230g) received an acute unilateral intracerebroventricular injection of soluble Ab1–42 on day 0 (5 nmol in 10ml) which was followed by 14 days
(starting one day before surgery) of i.p. injection of mefenamic acid (5mg kg 1) or vehicle. Animals were then tested in the novel object recognition task
on 14 d (a) and 35 d (b) post surgery. Discrimination index data are presented as meanþ s.e.m (n¼ 5–10). NS, not signiﬁcantly different, ###Po0.001
compared with vehicle/vehicle treated animals and **Po0.01 compared to Ab1-42/vehicle group. (c–f) 13–14 month old transgenic mouse model of
Alzheimer’s 3TgAD and wild-type (WT) control were treated with vehicle or 25mg kg 1 day 1 mefenamic acid. (c) On day 18 memory was assessed
with the novel object recognition task; discrimination index data are presented as meanþ s.e.m (n¼8–10). ###Po0.001 compared to vehicle/WTanimals
and **Po0.01 compared with vehicle/3TgAD mice. (d–f) Evaluation of Iba1 and IL-1b expressing microglia within the subicula of 3xTgAD and WTmice
following vehicle or mefenamic acid treatment. Microglial activation (d) and IL-1b expression (e) were evaluated and presented as meanþ s.e.m (n¼8–10).
###Po0.001 compared with vehicle/WT animals and **Po0.01 compared to vehicle/3TgAD mice. (f) Representative images of microglial activation
and IL-1b co-localization of 3TgAD and WTsubicula following vehicle or mefenamic acid treatment. Scale bars are 15 mm. Statistical analyses performed
using two-way ANOVA followed by Sidak corrected post hoc analysis.
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fenamate NSAIDs in NLRP3/IL-1b-associated diseases would also
inform and facilitate their future use.
For almost 30 years VRAC has been studied38. However, it is
only recently that the molecular identity of VRAC was discovered,
when two studies revealed that leucine rich repeat containing 8A
(LRRC8A) is an essential component39,40. LRRC8A assembles
channels with other LRRC8 proteins to reconstitute the
hypotonic-activated VRAC conductance39,40. These studies, and
our own data presented here, highlight VRAC as a potential
drug target in inﬂammatory disease, opening the door for the
development of new and improved molecular and pharmacological
tools to further dissect the importance of VRAC in the regulation
of the NLRP3 inﬂammasome and for the development of new
therapeutic strategies.
In summary, we have shown that fenamate NSAIDs are potent
and selective inhibitors of the NLRP3 inﬂammasome, which
act through inhibition of VRAC, a novel player in NLRP3
inﬂammasome regulation. Fenamate NSAID inhibition of NLRP3
is rapidly reversible which offers signiﬁcant clinical beneﬁt.
We have characterized their activity both in vitro and in vivo and
propose that fenamate NSAIDs can be rapidly repurposed as
drugs to target the NLRP3 inﬂammasome in inﬂammatory
diseases such as Alzheimer’s disease.
Methods
Materials. Pharmacological reagents were obtained from the following
manufacturers: Sigma (celecoxib, ibuprofen, diclofenac, ﬂufenamic acid,
meclofenamic acid, mefenamic acid, 5-nitro-2-(3-phenylpropylamino)benzoic acid
(NPPB), DIDS, 4-(2-Butyl-6,7-dichlor-2-cyclopentyl-indan-1-on-5-yl) oxybutyric
acid (DCPIB), Lipopolysaccharide from Escherichia coli O26:B6, ATP and
nigericin), Merck-Millipore (Ac-YVAD-CHO), Acros organics (MNS) and
Invivogen (MSU crystals, ultrapure ﬂagellin from Salmonella typhimurium).
All other materials/reagents were obtained from Sigma unless otherwise stated.
Cell culture and assays. iBMDMs41 were obtained from Clare Bryant (Department
of Veterinary Medicine, University of Cambridge). iBMDMs were cultured in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM), 10% fetal bovine serum (FBS, Life
Technologies), 100Uml 1 penicillin and 100mgml 1 streptomycin (PenStrep).
Cells were seeded overnight at 5 105ml 1 in 24- or 96-well plates. Cells were
primed with LPS then treated with drug or vehicle (DMSO) in serum-free media for
15min. Following drug incubation, inﬂammasomes were stimulated by adding ATP
(5mM) for 1 h. Supernatants were removed and analysed for IL-1b content by
ELISA (DuoSet, R&D systems) according to manufacturer’s instructions. Primary
mouse BMDMs were isolated by ﬂushing marrow from femurs and tibias of wild-
type C57BL/6 (Charles River) or NLRP3 / mice and cultured with L929 mouse
ﬁbroblast supernatant-conditioned media for 7–10 days. Human THP-1 peripheral
blood monocyte-like cells were cultured in RPMI-1640 Medium supplemented with
10% FBS, 100Uml 1, 100mgml 1 PenStrep, 20mM l-Glutamine and 55mM
2-mercaptoethanol (Life Technologies). Following priming for 4 h with LPS and
15min pre-treatment with drug in serum-free media, inﬂammasomes were activated
with nigericin (10mM) for 1 h, MSU crystals (250mgml 1) for 4 h, transfected
ultrapure ﬂagellin from Salmonella typhimurium (100ng per 100,000 cells) for 2 h, or
transfected DNA (pEF/V5-His A plasmid empty vector (Life Technologies, 66.7 ng
per 100K cells)) for 4 h. Transfections described above were performed using
Lipofectamine 3000 (Life Technologies) according to manufacturer’s instructions.
Western blotting. Western blot analysis was performed on supernatants for IL-1b
and caspase-1. Samples were run on 12% (IL-1b) or 15% (caspase-1) SDS
polyacrylamide gels. For caspase-1 blots THP-1 supernatants were concentrated
before preparation and loading by centrifugal ﬁltering (Amicon 10K centrifugal
ﬁlters) according to manufacturer’s instructions. Gels were transferred at 15V onto
nitrocellulose membrane (GE Life Sciences) using a Trans-Blot s.d. semi-dry
transfer system (Bio-Rad) before blocking with 5% w/v milk in phosphate-buffered
saline, 1% Tween 20 (Sigma) (PBST) for 1 h at room temperature. Membranes were
washed and incubated (4 C) overnight in goat anti-mouse IL-1b (100 ngml 1,
R&D Systems) or rabbit anti-human caspase-1 p10 (666.6 ngml 1, Santa Cruz)
primary antibodies in PBST, 0.1% bovine serum albumin (BSA). Following this,
membranes were washed and incubated with rabbit anti-goat (550 ngml 1) or
goat anti-rabbit IgG (250 mgml 1, Dako) in 5% milk in PBST for 1 h at room
temperature. Finally, membranes were washed and incubated in Amersham ECL
Western Blotting Detection Reagent (GE Life Sciences) before exposure on
photographic ﬁlm (Scientiﬁc Laboratory Supplies). Uncropped blots are presented
in Supplementary Fig. 12.
Cell death assays. Cell death was measured by assessing lactate dehydrogenase
release using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega)
according to manufacturer’s instructions.
ASC speck imaging. Live imaging of ASC speck formation was performed using
iBMDMs transfected to stably express ASC conjugated to mCherry protein. Mouse
ASC (Accession Number NM_023258) was ampliﬁed by PCR using primers ﬂanked
by gateway recombination sequences (forward primer: 50-ATGGGGCGGGCACG
AGATGCC-30 , reverse primer: 50-GCTCTGCTCCAGGTCCATCAC-30). A third
generation ‘pLNT’ lentiviral transfer system was used to express N-terminally
mCherry-tagged ampliﬁed ASC gene from a constitutive ubiquitin-ligase C
promoter42. Stably transduced cells were plated overnight at 5 105 cells per ml. The
following day, cells were primed with LPS (1mgml 1, 2 h). 1 h into priming,
Hoechst 33342 (2mgml 1, Immunochemistry) was added to aid identiﬁcation of
the cells. Following priming, media was changed to DMEM containing 25mM
HEPES pH 7.4 and cells transferred to a BD Pathway Bioimager 855 (BD
Biosciences) and imaged at 37 C. Cells were pre-treated with drug or vehicle for
15min before imaging. Images were acquired using a  20/0.75 UApo objective and
the following ﬁlter setups: Hoechst Ex. 360/10 Di. Em. 84101; mCherry Ex. 555/28
Di. Em. 84101. Images were collected and a montage of 3 3 was created. Following
drug incubation, cells were stimulated by addition of ATP (5mM) directly into the
well and imaged as described for 30min. Specks were quantiﬁed by blind-counting
nine separate ﬁelds of view (1.2mm2) using ImageJ.
Cysteine modiﬁcation and NMR. Flufenamic acid or MNS (0.05 mmol) was
dissolved in DMSO-d6 (400 ml) in an NMR tube. N-Acetyl-L-cysteine methyl ester
(17.7mg, 0.10 mmol) solubilized in DMSO-d6 (100 ml) was added and an NMR
spectrum was recorded every 10min after the addition for 2 h and then every 1 h
until 24 h. A Bruker Avance 400 spectrometer was used to record 1H spectra at
300.1MHz. Chemical shifts are deﬁned in parts per million and referenced against
tetramethylsilane (d¼ 0). NMR analysis was conducted using Bruker’s TopSpin
software package.
Electrophysiological recordings. Membrane currents were measured using the
whole-cell conﬁguration of the patch-clamp technique. An EPC-10 patch-clamp
ampliﬁer (HEKA) was interfaced to a computer for pulse application and data
recording using the programme PatchMaster (HEKA). Patch electrodes of
3-5MO were fabricated on a two-stage puller (Narishige PC-10) from borosilicate
glass (Hilgenberg). For all electrophysiological experiments, 105 iBMDM cells were
seeded in 24-well plates on glass coverslips and primed the next day with
1 mgml 1 LPS for 4 h. For electrophysiological recordings of ATP-induced cation
currents, patch electrodes were ﬁlled with an intracellular solution containing (in
mM): KCl, 120; HEPES, 10; EGTA, 11; CaCl2, 1; MgCl2, 2 (pH 7.3). LPS-primed
iBMDM cells were superfused with extracellular solution containing (in mM):
NaCl, 130; KCl, 5; HEPES, 10; D-glucose, 10; CaCl2, 2; MgCl2, 1 (pH 7.4). The effect
of ﬂufenamic/mefenamic acid was investigated after a stable cation current was
induced by application of 5mM ATP. DMSO was used as vehicle control in these
experiments. Leak-subtracted currents were analysed at þ 90mV and data are
presented as mean values±s.e.m. For volume-regulated Cl current recordings,
patch electrodes were ﬁlled with the following intracellular solution
(in mM): N-Methyl-D-Glucamine-Chloride (NMG-Cl), 120; HEPES, 10; EGTA, 11;
CaCl2, 1; MgCl2, 2; Na2ATP, 3 (pH 7.3). Cells were kept in iso-osmolar
extracellular solution containing (in mM): NMG-Cl, 50; HEPES, 10; D-glucose, 10;
CaCl2, 2; MgCl2, 1; D-mannitol, 170 (300 mosmol per kg, pH 7.3). To activate
VRAC currents, superfusion was changed to hypo-osmolar extracellular solution
containing no D-mannitol (130 mosmol per kg, pH 7.3). To permit a rapid
exchange of solutions for drug application, cells were continuously superfused
using a four-barrel microperfusion pipette positioned near the recorded cell.
Extracellular solutions containing the indicated NSAID were applied after stable
activation of Cl currents; DMSO was used as vehicle control. All recordings were
made at a temperature of 23–26 C. Whole-cell currents were ﬁltered at 3 kHz and
stored for subsequent analyses. Analyses of leak-subtracted currents at þ 90mV
were performed with the programme FitMaster (HEKA).
Fluorescence imaging. 105 iBMDMs were seeded one day before experiments on
glass coverslips in 24-well plates and primed with LPS (1mgml 1, 4 h) before
ﬂuorescence imaging experiments. Subsequently cells were loaded with ﬂuorescent
dyes in Naþ /Kþ containing extracellular solution at room temperature (20–23 C):
for Ca2þ imaging experiments with 3mM fura-2-acetoxymethylester (Fura-2-AM)
for 30min, for Naþ imaging experiments with 10mM sodium-binding benzofuran-
isophthalate acetoxymethyl ester (SBFI-AM; both dyes from Molecular Probes) for
60min. After washing with extracellular solution, glass coverslips were mounted in a
chamber on an inverted Olympus IX50 microscope equipped with a  40 water
immersion objective UApo/340 (Olympus Optical, Co.). The ﬂuorescence imaging
system consisted of a monochromator, a charge-coupled device (CCD) camera and a
Windows 7 based image processing software (Till Photonics). Cells were exposed to
alternating 340±5 and 380±5 nm wavelengths of UV light and emission light was
passed through a 400 nm dichroic mirror and a 420nm long pass emission ﬁlter
(both Olympus) before image acquisition by the CCD camera. Images were collected
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every 20 s. Cells were continuously superfused with Naþ /Kþ -containing
extracellular solution using a four-barrel microperfusion pipette positioned in close
proximity to the viewing ﬁeld. Ca2þ and Naþ inﬂux was induced by extracellular
solution containing 5mM ATP in the presence or absence of mefenamic acid.
DMSO was used as vehicle control in all experiments. For each individual cell,
mean intensity values from background subtracted pictures were determined
and ratios F340/F380 calculated, accordingly. Data are presented as mean
values±s.e.m.
Regulatory volume decrease. THP-1 cells were adjusted to a density of 1 106
cells per ml in RPMI media (10% FBS, 1% P/S, 1% Glutamine) and primed with
LPS (1mgml 1, 4 h). A 300 mOsm isotonic buffer was prepared consisting of
147mM NaCl, 10mM HEPES, 13mM glucose, 2mM KCl, 2mM CaCl2, 1mM
MgCl2, adjusted to pH 7.4 using NaOH. From this a 90 mOsm hypotonic buffer
was achieved by diluting the isotonic buffer 1:4 with sterile water. Cell size and
viability measurements were performed on a BD FACSVerse ﬂow cytometer (BD).
THP-1 cells were incubated in a 37 C water bath and a series of measurements
were taken for 60min with 10,000 events recorded each run. Cell swelling
was initiated by aspiration of isotonic buffer followed by addition of
hypotonic buffer containing respective drugs. Cell volume measurements by
forward scatter width were normalized against the average cell volume before
hypotonic stimulus.
Animal experiments. Animals were maintained under standard laboratory
conditions: ambient temperatures of 21 C (±2 C), humidity of 40–50%, 12 h light
cycle, ad libitum access to water and standard rodent chow. All surgeries were
performed with the surgeon concealed to the treatment and/or genotype, and all
behavioural and histological analyses were performed by a blinded observer.
Treatments were randomly allocated. All animal experiments were carried out in
accordance with the United Kingdom Animals (Scientiﬁc Procedures) Act 1986
and approved by the Home Ofﬁce and the local Animal Ethical Review Group,
University of Manchester.
Air pouch inﬂammation model. The air pouch model was used to assess the
NLRP3-dependent response to MSU crystals23. On day 0 a subcutaneous air pouch
was raised in the dorsum of male C57BL/6 mice (30–35 g) by the injection of 4ml
sterile air (ﬁltered through 0.22 mm pore size) with a 25 gauge needle. This was
repeated on day 3. On day 7, pouches were injected with 1ml MSU crystals
(3mgml 1 in sterile saline) or vehicle with or without ﬂufenamic acid
(20mg kg 1 in sterile saline, 5% Cremaphor EL, 5% DMSO) or vehicle. Following
6 h incubation, mice were killed by raising the concentration of CO2 and pouches
were lavaged by injecting 4ml PBS, 1% BSA, 5mM EDTA. Lavage was collected
from each animal, passed through 100mm cell strainers before analysis by ELISA as
above or by ﬂow cytometry. For the ﬂow cytometry cells were adjusted to a density
of 5 106 cells per ml in ice-cold PBS, 1% BSA, 5mM EDTA before plating out on
a clear V-bottomed 96-well plate (Thermo Scientiﬁc) at 200ml per well. Cells were
stained with antibodies (Anti-CD45 conjugated to FITC at 1 ngml 1, anti-Ly6G
conjugated to APC at 1 ngml 1 and anti-F4/80 conjugated to PE at 2.5 ngml 1,
all Tonbo Biosciences) for 45min on ice in the dark before washing twice and
ﬁxing in paraformaldehyde (3.7–4.1% in PBS, 200 ml) for 15min at room
temperature. The following day, cells were analysed on a FACSVerse ﬂow
cytometer (BD Biosciences) with BD FACSuite software.
Peritoneal inﬂammation model. Randomly allocated wild-type (C57BL/6) and
NLRP3 KO mice (male, 30–35 g) were dosed i.p. with mefenamic acid
(50mg kg 1, 25% (w/v) (2-hydroxy)propyl-b-cyclodextrin in PBS solubilized with
0.1M NaOH then pH adjusted to 7.4), cyclodextrin vehicle or the selective NLRP3
inhibitor MCC950 (50mg kg 1, PBS) and LPS (1mg in 0.5ml, PBS) for 4 h.
Following LPS prime, mice were anaesthetized with isoﬂurane (induced at
3–4% in 33% O2, 67% NO2, maintained at 1–2% whilst kept at 37 C on a
heat blanket) before injection with mefenamic acid, MCC950 or vehicle as
before and ATP (0.5ml, 100mM, PBS) or PBS for 15min. Peritoneums
were lavaged and plasma taken by cardiac puncture before analysis by ELISA for
IL-1b and IL-1a.
Ab-induced memory deﬁcit. Female Lister Hooded rats initially weighing
200–230 g (n¼ 5–10) were used for the following study. Soluble Ab1–42 oligomers
were prepared at a concentration of 0.5mM in sterile 0.1M phosphate buffer saline
as previously described29,43. Rats were anaesthetized with isoﬂurane (induction at
4% in O2 and maintained at 2% in O2) and placed on a stereotaxic frame. Ab
oligomers were injected in the left ventricle (bregma:  0.8mm anteroposterior,
 1.5mm lateral,  4.5mm dorsoventral at a rate of 2.5 ml min 1; ﬁnal volume:
10ml, 5 nmol. Rats underwent surgery (vehicle or Ab1–42 oligomers) on day 0. Rats
were treated with daily intraperitoneal (i.p.) injections of vehicle or mefenamic acid
(5mg kg 1, 25% (w/v) (2-hydroxy)propyl-b-cyclodextrin in saline solubilized with
0.1M NaOH then the pH was adjusted to 7.4) from day  1 to day 13. We
estimated based on previous literature that the dose of mefenamic acid
administered here was likely to be efﬁcacious against the inﬂammasome44,45.
Treatment was then stopped until the last day of testing (day 35).
Transgenic mouse model of Alzheimer’s disease. Male 3xTgAD mice
expressing mutant PS1M146V, APPSwe, TauP301L, and control wild-type
(129/C57BL6) mice were originally supplied by Frank LaFerla (Irvine, CA, USA)46.
At 13–14 months old 3TgAD (n¼ 20) and wild-type (n¼ 20) mice were
randomly allocated into mefenamic acid- or vehicle- (60% DMSO, 40%
Cremophor A25 Sigma Aldrich) treated groups. The animals were anaesthetized
with 2 to 5% isoﬂurane (30% O2 and 70% N2O) and implanted with ALZET 200ml
minipump. After four days of priming in the animal, the minipumps
reached a sustained administration rate of approximately 25mg kg 1 day 1
for 28 days. 36 days after minipump implantation the animals were terminally
anaesthetized with 2 to 5% isoﬂurane (30% O2 and 70% N2O) and then
transcardially perfused with 0.9% saline. The brains were removed and
ﬁxed by immersion in 4% paraformaldehyde in 0.2M phosphate buffer for 24 h
followed by a 24 h immersion in 30% sucrose/PBS and then frozen on dry ice.
The brains were stored at  80 C until analysis. One mouse died during
minipump implantation.
Novel object recognition. NOR was performed as previously described47,48.
Brieﬂy, the rats were placed in the NOR box (52 52 31 cm) and left free to
explore two copies of the same object for 3min (Acquisition phase). Animals were
taken out of the box for an inter-trial interval (2min) then placed back in the same
box for a further 3min, then presented with an identical copy of the previous object
and a novel object (Retention phase). Both sessions are recorded on video and the
time spent exploring each object was scored. The discrimination index is calculated
as (novel familiar)/(novelþ familiar). Rats were tested in the NOR task on day 14
and day 35 after surgery. NOR was also performed using the 3TgAD transgenic
mice with a white Perspex circular arena 30 cm in diameter, 8min acquisition
phase, 1 h inter-trial interval and a 4min retention phase. This was performed 18
days after osmotic minipump implantation. Three mice were excluded as they
failed to explore for at least 4 s.
Immunohistochemistry. Free-ﬂoating serial 30 mm sections were taken from the
wild-type and 3TgAD mice using a microtome (Bright Instruments Ltd., UK)
and stored in cryoprotectant (30% ethylene glycol, 20% glycerol in 0.2M phosphate
buffer). Sections were washed (3 ) in PBS for 5min and blocked for 1 h in 10%
normal donkey serum (NDS) in 0.3% Triton X-100 PBS (PBST). This was followed
by an overnight incubation with primary antibody in 2% NDS in PBST at 4 C.
Speciﬁcity controls were performed on additional 3TgAD sections with omission
of the primary antibodies. Sections were then washed (3 ) in PBST and then
incubated in with Alexa-488 (visualizing Iba1) and Alexa-594 (visualizing IL-1b)
conjugated secondary antibodies (Invitrogen) at 1:500 dilution in 2% NDS in PBST
for 2 h. Sections were then washed (3 ) in PBST and mounted using ProLong
Gold Antifade Mountant with DAPI (Thermo Fischer Scientiﬁc, Inc., USA). Pri-
mary antibodies used were anti-Iba1 (1:1000, Wako Ltd) and anti- IL-1b (1:200,
R&D Systems).
Microscopy and quantiﬁcation of microglial activation. Images were collected
on an Olympus BX51 upright microscope using a  40 objective and captured
using a Coolsnap ES camera. High power ﬁeld images were taken of the subiculum,
CA1 region of the hippocampus and the outer cortex at bregma  2.3mm,
 2.6mm and  2.9mm as shown in Supplementary Fig. 10a. These regions were
chosen based on previous publications on pathology progression in 3TgAD
mice30. Total microglia were counted and the percentage of IL-1b positive
microglia recorded. Microglial morphologies were scored on an activation scale of
0 to 3 based on microglia categories previously described31. Scores of 0–1 were
considered resting, and 2–3 considered activated (Supplementary Fig. 10b). Each
section was treated as a technical replicate, as such scores were averaged for each
animal. Counting and scoring were performed by a blinded observer. Example
images were collected on a Leica TCS SP5 AOBS upright confocal using a  63
objective and  2 confocal zoom. Images were overlaid and stacked using Fiji
Image J49.
Statistical analyses. Data are presented as mean valuesþ standard error of the
mean (s.e.m). Statistical analyses performed were one-sample t-tests, one-way
analysis of variance (ANOVA) and two-way ANOVA tests with Sidak corrected
post hoc. Equal variance and normality were assessed with the Levene’s test and the
Shapiro–wilk test, respectively, and appropriate transformations were applied when
necessary. Accepted levels of signiﬁcance were *Po0.05, **Po0.01, ***Po0.001.
Statistical analyses were carried out using GraphPad Prism or SPSS. Images were
processed using Fiji ImageJ49 and analysed by manual counting with experimenter
blinded to image identity throughout. Flow cytometry data were analysed and
populations quantiﬁed using FlowJo V10.
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Data availability. The data that support the ﬁndings of this study are available
from the corresponding author on request.
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